These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of heart failure with enoximone, a new phosphodiesterase inhibitor. Düsseldorf, Federal Republic of Germany. September 25-27, 1987. Proceedings. J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S1-S83. PubMed ID: 2480479 [No Abstract] [Full Text] [Related]
6. Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method. Installe E, De Coster P, Gonzalez M, Brichant C, Lessire H, Cauwe F. Eur Heart J; 1991 Sep; 12(9):985-93. PubMed ID: 1834466 [Abstract] [Full Text] [Related]
8. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. Colucci WS, Wright RF, Braunwald E. N Engl J Med; 1986 Feb 06; 314(6):349-58. PubMed ID: 2418353 [No Abstract] [Full Text] [Related]
10. Beneficial haemodynamic effects of enoximone in cardiac transplant candidates awaiting a suitable donor. Vulser C, Guillemain R, Amrein C, Trinquier R, Farge D, Dreyfus G, Couetil JP, Carpentier A, Cousin MT. J Cardiothorac Anesth; 1989 Oct 06; 3(5 Suppl 1):11. PubMed ID: 2535300 [No Abstract] [Full Text] [Related]
11. [Long-term therapy of chronic cardiac insufficiency using enoximone]. Treese N, Erbel R, Rhein S, Diefenbach C, Alken RG, Mohr-Kahaly S, Meyer J. Dtsch Med Wochenschr; 1987 Jul 24; 112(30):1163-9. PubMed ID: 2956080 [Abstract] [Full Text] [Related]
12. Comparison of cardiovascular effects of dobutamine and enoximone in treatment of low cardiac output syndrome after valvular surgery--preliminary results. George M, Lehot JJ, Bastien O, Durand PG, Estanove S. J Cardiothorac Anesth; 1989 Oct 24; 3(5 Suppl 1):12. PubMed ID: 2535301 [No Abstract] [Full Text] [Related]
13. Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment. Dubourg O, Delorme G, Hardy A, Beauchet A, Tarral A, Bourdarias JP. Int J Cardiol; 1990 Jul 24; 28 Suppl 1():S33-42; discussion S43. PubMed ID: 2145237 [Abstract] [Full Text] [Related]
14. Effects of enoximone on quality of life. Baligadoo SJ, Subratty H, Manraz M, Tarral A, Maiti D, Murday M. Int J Cardiol; 1990 Jul 24; 28 Suppl 1():S29-32. PubMed ID: 2145235 [Abstract] [Full Text] [Related]
15. [Tolerance of enoximone in patients with heart failure]. Gilfrich HJ, Dieterich HA. Z Kardiol; 1991 Jul 24; 80 Suppl 4():93-7. PubMed ID: 1833904 [Abstract] [Full Text] [Related]
16. Differential hemodynamic effects of oral enoximone in severe congestive heart failure. Murali S, Uretsky BF, Betschart AR, Tokarczyk TR, Kolesar JA, Reddy PS. Am J Cardiol; 1990 Feb 15; 65(7):515-9. PubMed ID: 2137668 [No Abstract] [Full Text] [Related]
17. Electrophysiologic effects of enoximone in patients with congestive heart failure. Hohnloser SH, Zehender M, Geibel A, Meinertz T, Just H. J Cardiovasc Pharmacol; 1989 Feb 15; 14 Suppl 1():S29-32. PubMed ID: 2480482 [Abstract] [Full Text] [Related]
18. [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]. Saborowski F, Peters P, Schneider M. Z Kardiol; 1991 Feb 15; 80 Suppl 4():63-7. PubMed ID: 1833900 [Abstract] [Full Text] [Related]
19. [Hemodynamic effects of enoximone--comparative studies of heart surgery patients]. Boldt J, Hempelmann G. Z Kardiol; 1991 Feb 15; 80 Suppl 4():41-6. PubMed ID: 1833896 [Abstract] [Full Text] [Related]